126 results
Page 3 of 7
8-K
EX-99.1
8q0 mcopk1shy8
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.1
8bs ozgr5bzak2silizw
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
ft1wg
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
zk6w5bmozh c5vswo8kh
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
98c7yh 4e9ij
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
4eew4f ke
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
vv9 ybb66p
5 May 20
Prospectus supplement for primary offering
5:05pm
424B5
rntymr 0uki7
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
37wh uk6pw
2 Mar 20
Prospectus supplement for primary offering
4:21pm
S-3ASR
y11y0s
26 Feb 20
Automatic shelf registration
8:35am
8-K
EX-99.1
j8tlzc3 9a8r
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
t3y11a
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
5y9z6 0sxlr6atka57u
6 Aug 19
Results of Operations and Financial Condition
7:13am